|
1
|
Bade BC and Dela Cruz CS: Lung cancer
2020: Epidemiology, etiology, and prevention. Clin Chest Med.
41:1–24. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Spiro SG and Silvestri GA: One hundred
years of lung cancer. Am J Respir Crit Care Med. 172:523–529.
2005.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rébé C and Ghiringhelli F: Cytotoxic
effects of chemotherapy on cancer and immune cells: How can it be
modulated to generate novel therapeutic strategies? Future Oncol.
11:2645–2654. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Su CY, Ming QL, Rahman K, Han T and Qin
LP: Salvia miltiorrhiza: Traditional medicinal uses,
chemistry, and pharmacology. Chin J Nat Med. 13:163–182.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhang JP, Zhang YY, Zhang Y, Gao YG, Ma
JJ, Wang N, Wang JY, Xie Y, Zhang FH and Chu L: Salvia
miltiorrhiza (Danshen) injection ameliorates iron
overload-induced cardiac damage in mice. Planta Med. 79:744–752.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Xiong XJ, Wang Z and Wang J: Innovative
strategy in treating angina pectoris with Chinese patent medicines
by promoting blood circulation and removing blood stasis:
Experience from combination therapy in Chinese medicine. Curr Vasc
Pharmacol. 13:540–553. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tawil N and Rak J: Blood coagulation and
cancer genes. Best Pract Res Clin Haematol.
35(101349)2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Qi Y: Progress of modern research on tumor
blood stasis syndrome and its treatment with the method of
promoting blood circulation by removing blood stasis. J Tradit Chin
Med. 15:68–76. 1995.PubMed/NCBI
|
|
10
|
Li ZM, Xu SW and Liu PQ: Salvia
miltiorrhiza Burge (Danshen): A golden herbal medicine in
cardiovascular therapeutics. Acta Pharmacol Sin. 39:802–824.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liang WY, Chen WJ, Yang GH, Zhu D, Mao X,
Shao YY, Wu LF, Zhang XX and Zhang LZ: Research progress on
salvianolic acids of Salvia miltiorrhiza. Zhongguo Zhong Yao
Za Zhi. 41:806–812. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
12
|
Wang J, Xu J, Gong X, Yang M, Zhang C and
Li M: Biosynthesis, chemistry, and pharmacology of polyphenols from
Chinese Salvia species: A review. Molecules. 24(155)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pang H, Wu L, Tang Y, Zhou G, Qu C and
Duan JA: Chemical analysis of the herbal medicine Salviae
miltiorrhizae Radix et Rhizoma (Danshen). Molecules.
21(51)2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Guo R, Li L, Su J, Li S, Duncan SE, Liu Z
and Fan G: Pharmacological activity and mechanism of tanshinone IIA
in related diseases. Drug Des Devel Ther. 14:4735–4748.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu MZ, Huang YS and Xiao WQ: No promoting
effects of sodium tanshinone II-A sulfonate on growth and
metastasis of Lewis carcinoma. Zhongguo Yao Li Xue Bao. 12:534–537.
1991.PubMed/NCBI(In Chinese).
|
|
16
|
Zhou J, Jiang YY, Chen H, Wu YC and Zhang
L: Tanshinone I attenuates the malignant biological properties of
ovarian cancer by inducing apoptosis and autophagy via the
inactivation of PI3K/AKT/mTOR pathway. Cell Prolif.
53(e12739)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yin ZK, Liu ZZ, Yuan X, Feng ZM, Jiang JS,
Zhang X, Zhang PC and Yang YN: Thirteen undescribed diterpenoid
quinones derived from the rhizomes of Salvia miltiorrhiza
and their anti-tumor activities. Phytochemistry.
191(112902)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang Y and Zhang D: Tanshinol inhibits
growth of malignant melanoma cells via regulating miR-1207-5p/CHPF
pathway. Arch Dermatol Res. 312:373–383. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ye YT, Zhong W, Sun P, Wang D, Wang C, Hu
LM and Qian JQ: Apoptosis induced by the methanol extract of
Salvia miltiorrhiza Bunge in non-small cell lung cancer
through PTEN-mediated inhibition of PI3K/Akt pathway. J
Ethnopharmacol. 200:107–116. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen X, Guo J, Bao J, Lu J and Wang Y: The
anticancer properties of Salvia miltiorrhiza Bunge
(Danshen): A systematic review. Med Res Rev. 34:768–794.
2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Qian W, Wang Z, Xu T and Li D:
Anti-apoptotic effects and mechanisms of salvianolic acid A on
cardiomyocytes in ischemia-reperfusion injury. Histol Histopathol.
34:223–231. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tang SM, Xing XY, Deng XH, Zhao NN, Li G,
Yang RC, Sun GB and Sun XB: Research progress of Guanxin Danshen
formula and its effective components in treating coronary artery
heart disease. Zhongguo Zhong Yao Za Zhi. 41:3721–3726.
2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
23
|
Ren J, Fu L, Nile SH, Zhang J and Kai G:
Salvia miltiorrhiza in treating cardiovascular diseases: A
review on its pharmacological and clinical applications. Front
Pharmacol. 10(753)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shi MJ, Yan XL, Dong BS, Yang WN, Su SB
and Zhang H: A network pharmacology approach to investigating the
mechanism of Tanshinone IIA for the treatment of liver fibrosis. J
Ethnopharmacol. 253(112689)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tang YX, Liu M, Liu L, Zhen BR, Wang TT,
Li N, Lv N, Zhu Z, Sun G, Wang X and Chen S: Lipophilic
constituents in Salvia miltiorrhiza Inhibit activation of
the hepatic stellate cells by suppressing the JAK1/STAT3 signaling
pathway: A network pharmacology study and experimental validation.
Front Pharmacol. 13(770344)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tseng YJ, Hung YC, Kuo CE, Chung CJ, Hsu
CY, Muo CH, Hsu SF and Hu WL: Prescription of #adix Salvia
miltiorrhiza in Taiwan: A population-based study using the
national health insurance research database. Front Pharmacol.
12(719519)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lee SR, Jeon H, Kwon JE, Suh H, Kim BH,
Yun MK, Lim YJ and Kang SC: Anti-osteoporotic effects of Salvia
miltiorrhiza Bunge EtOH extract both in ovariectomized and
naturally menopausal mouse models. J Ethnopharmacol.
258(112874)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen J and Wang Y, Wang S, Zhao X, Zhao L
and Wang Y: Salvianolic acid B and ferulic acid synergistically
promote angiogenesis in HUVECs and zebrafish via regulating VEGF
signaling. J Ethnopharmacol. 283(114667)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xu X, Xu H, Shang Y, Zhu R, Hong X, Song Z
and Yang Z: Development of the general chapters of the Chinese
Pharmacopoeia 2020 edition: A review. J Pharm Anal. 11:398–404.
2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nie JM and Li HF: Therapeutic effects of
Salvia miltiorrhiza injection combined with telmisartan in
patients with diabetic nephropathy by influencing collagen IV and
fibronectin: A case-control study. Exp Ther Med. 16:3405–3412.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang H, Kang Y, Li H, Huang S, Li W, Zheng
M, Huang R, Lei B and Yang X: Salvia miltiorrhiza Derived
carbon dots and their heat stress tolerance of Italian lettuce by
promoting growth and enhancing antioxidant enzyme activity. ACS
Omega. 6:32262–32269. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Duan ZZ, Li YH, Li YY, Fan GW, Chang YX,
Yu B and Gao XM: Danhong injection protects cardiomyocytes against
hypoxia/reoxygenation- and H2O2-induced
injury by inhibiting mitochondrial permeability transition pore
opening. J Ethnopharmacol. 175:617–625. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Li L, Sha Z, Wang Y, Yang D, Li J, Duan Z,
Wang H and Li Y: Pre-treatment with a combination of Shenmai and
Danshen injection protects cardiomyocytes against
hypoxia/reoxygenation- and H2O2-induced
injury by inhibiting mitochondrial permeability transition pore
opening. Exp Ther Med. 17:4643–4652. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang Y, Shi Y, Zou J, Zhang X, Liang Y,
Tai J, Cui C, Wang M and Guo D: Network pharmacology exploration
reveals a common mechanism in the treatment of
cardio-cerebrovascular disease with Salvia miltiorrhiza
Burge. and Carthamus tinctorius L. BMC Complement Med Ther.
20(351)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jin Y, Yu L, Xu F, Zhou J, Xiong B, Tang
Y, Li X, Liu L and Jin W: Pharmacokinetics of active ingredients of
Salvia miltiorrhiza and Carthamus tinctorius in
compatibility in normal and cerebral ischemia rats: A comparative
study. Eur J Drug Metab Pharmacokinet. 45:273–284. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sun G, Li X, Wei J, Zhang T, Li B, Chen M,
Wang Y, Chen K and Li Y: Pharmacodynamic substances in Salvia
miltiorrhiza for prevention and treatment of hyperlipidemia and
coronary heart disease based on lipidomics technology and network
pharmacology analysis. Biomed Pharmacother.
141(111846)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhang Y, Wang J, Liu YM, Chen YY, Yang XC
and Duan L: The synergistic effects of astragalus mongholicus and
Salvia miltiorrhiza on coronary heart disease identified by
network pharmacology and experiment. Drug Des Devel Ther.
15:4053–4069. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Subedi L and Gaire BP: Tanshinone IIA: A
phytochemical as a promising drug candidate for neurodegenerative
diseases. Pharmacol Res. 169(105661)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chong CM, Su H, Lu JJ and Wang Y: The
effects of bioactive components from the rhizome of Salvia
miltiorrhiza (Danshen) on the characteristics of Alzheimer's
disease. Chin Med. 14(19)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Guo Y, Li Y, Xue L, Severino RP, Gao S,
Niu J, Qin LP, Zhang D and Brömme D: Salvia miltiorrhiza: An
ancient Chinese herbal medicine as a source for anti-osteoporotic
drugs. J Ethnopharmacol. 155:1401–1416. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Guo Y, Dong X, Zhang R, Zhong Y, Yang P
and Zhang SY: Salvia miltiorrhiza improves Alzheimer's
disease: A protocol for systematic review and meta-analysis.
Medicine (Baltimore). 99(e21924)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Liu L and Zhang HQ: Effects of Danshen
Decoction on experimental gastric ulcer in rats and mice. Zhong Xi
Yi Jie He Xue Bao. 3:35–38. 2005.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
43
|
He S, Yang Y, Liu X, Huang W and Zhang X,
Yang S and Zhang X: Compound astragalus and Salvia
miltiorrhiza extract inhibits cell proliferation, invasion and
collagen synthesis in keloid fibroblasts by mediating transforming
growth factor-β / Smad pathway. Br J Dermatol. 166:564–574.
2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhang W, Li J, Yang P, Wang G, Yue Y,
Zhong Y, Liu H, Gui D, Xu Y and Wang N: Efficacy and safety of
Salvia miltiorrhiza for treating chronic kidney diseases: A
systematic review and meta-analysis. Evid Based Complement Alternat
Med. 2022(2117433)2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ahn YM, Kim SK, Lee SH, Ahn SY, Kang SW,
Chung JH, Kim SD and Lee BC: Renoprotective effect of tanshinone
IIA, an active component of Salvia miltiorrhiza, on rats
with chronic kidney disease. Phytother Res. 24:1886–1892.
2010.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Cao T, Lu Y, Zhu M, Cheng J, Ye B, Fang N,
Cui Y, Xue B, Lari Najafi M and Kazemi E: Effects of Salvia
miltiorrhiza and Radix astragali on the TGF-β/Smad/Wnt pathway
and the pathological process of liver fibrosis in rats. Cell Mol
Biol (Noisy-le-grand). 66:46–51. 2020.PubMed/NCBI
|
|
47
|
Shi M, Huang F, Deng C, Wang Y and Kai G:
Bioactivities, biosynthesis and biotechnological production of
phenolic acids in Salvia miltiorrhiza. Crit Rev Food Sci
Nutr. 59:953–964. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Du G, Song J, Du L, Zhang L, Qiang G, Wang
S, Yang X and Fang L: Chemical and pharmacological research on the
polyphenol acids isolated from Danshen: A review of salvianolic
acids. Adv Pharmacol. 87:1–41. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Xu H, Li Y, Che X, Tian H, Fan H and Liu
K: Metabolism of salvianolic acid A and antioxidant activities of
its methylated metabolites. Drug Metab Dispos. 42:274–281.
2014.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Jin YM, Tao XM, Shi YN, Lu Y and Mei JY:
Salvianolic acid B exerts a protective effect in acute liver injury
by regulating the Nrf2/HO-1 signaling pathway. Can J Physiol
Pharmacol. 98:162–168. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Jiang Z, Gao W and Huang L: Tanshinones,
critical pharmacological components in Salvia miltiorrhiza.
Front Pharmacol. 10(202)2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Shahzadi I, Ali Z, Bukhari S, Narula AS,
Mirza B and Mohammadinejad R: Possible applications of salvianolic
acid B against different cancers. Explor Target Antitumor Ther.
1:218–238. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Zeng W, Shan W, Gao L, Gao D, Hu Y, Wang
G, Zhang N, Li Z, Tian X, Xu W, et al: Inhibition of HMGB1 release
via salvianolic acid B-mediated SIRT1 up-regulation protects rats
against non-alcoholic fatty liver disease. Sci Rep.
5(16013)2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Raudenská M, Navrátil J, Gumulec J and
Masařík M: Mechanobiology of cancerogenesis. Klin Onkol.
34:202–210. 2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chen L, Wang HJ, Xie W, Yao Y, Zhang YS
and Wang H: Cryptotanshinone inhibits lung tumorigenesis and
induces apoptosis in cancer cells in vitro and in
vivo. Mol Med Rep. 9:2447–2452. 2014.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Li Y, Gong Y, Li L, Abdolmaleky HM and
Zhou JR: Bioactive tanshinone I inhibits the growth of lung cancer
in part via downregulation of Aurora A function. Mol Carcinog.
52:535–543. 2013.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Chiu TL and Su CC: Tanshinone IIA induces
apoptosis in human lung cancer A549 cells through the induction of
reactive oxygen species and decreasing the mitochondrial membrane
potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
|
|
58
|
Han G, Wang Y, Liu T, Gao J, Duan F, Chen
M, Yang Y and Wu C: Salvianolic acid B acts against non-small cell
lung cancer A549 cells via inactivation of the MAPK and Smad2/3
signaling pathways. Mol Med Rep. 25(184)2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Warfel NA and El-Deiry WS: p21WAF1 and
tumourigenesis: 20 Years after. Curr Opin Oncol. 25:52–58.
2013.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Guan Z, Chen J, Li X and Dong N:
Tanshinone IIA induces ferroptosis in gastric cancer cells through
p53-mediated SLC7A11 down-regulation. Biosci Rep.
40(BSR20201807)2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Li Z, Zhang Y, Zhou Y, Wang F, Yin C, Ding
L and Zhang S: Tanshinone IIA suppresses the progression of lung
adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1
pathway. Sci Rep. 11(23681)2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Li J, Wang K, Chen X, Meng H, Song M, Wang
Y, Xu X and Bai Y: Transcriptional activation of microRNA-34a by
NF-kappa B in human esophageal cancer cells. BMC Mol Biol.
13(4)2012.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Sun C, Su S, Zhu Y, Guo J, Guo S, Qian D,
Yu L, Gu W and Duan JA: Salvia miltiorrhiza stem-leaf active
components of salvianolic acids and flavonoids improved the
hemorheological disorder and vascular endothelial function on
microcirculation dysfunction rats. Phytother Res. 34:1704–1720.
2020.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Li HY, Li Y, Yan CH, Li LN and Chen XG:
Inhibition of tumor growth by S-3-1, a synthetic intermediate of
salvianolic acid A. J Asian Nat Prod Res. 4:271–280.
2002.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Chen XG, Li Y, Yan CH, Li LN and Han R:
Cancer chemopreventive activities of S-3-1, a synthetic derivative
of danshinone. J Asian Nat Prod Res. 3:63–75. 2001.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Qi P, Li Y, Liu X, Jafari FA, Zhang X, Sun
Q and Ma Z: Cryptotanshinone suppresses non-small cell lung cancer
via microRNA-146a-5p/EGFR axis. Int J Biol Sci. 15:1072–1079.
2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Bi L, Chen J, Yuan X, Jiang Z and Chen W:
Salvianolic acid A positively regulates PTEN protein level and
inhibits growth of A549 lung cancer cells. Biomed Rep. 1:213–217.
2013.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Shi H, Zhang Q, Li H, Chu T, Jin H and Mao
S: Growth inhibition of tanshinones on SPC-A-1 cell line and their
structure-activity relationship. Zhongguo Fei Ai Za Zhi. 14:7–12.
2011.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
69
|
Miyazaki T and Arai S: Two distinct
controls of mitotic cdk1/cyclin B1 activity requisite for cell
growth prior to cell division. Cell Cycle. 6:1419–1425.
2007.PubMed/NCBI
|
|
70
|
Zhang J, Wen G, Sun L, Yuan W, Wang R,
Zeng Q, Zhang G and Yu B: Cryptotanshinone inhibits cellular
proliferation of human lung cancer cells through downregulation
ofIGF-1R/PI3K/Akt signaling pathway. Oncol Rep. 40:2926–2934.
2018.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Chen Y, Li H, Li M, Niu S, Wang J, Shao H,
Li T and Wang H: Salvia miltiorrhiza polysaccharide
activates T Lymphocytes of cancer patients through activation of
TLRs mediated-MAPK and-NF-κB signaling pathways. J Ethnopharmacol.
200:165–173. 2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Bandi N and Vassella E: miR-34a and
miR-15a/16 are co-regulated in non-small cell lung cancer and
control cell cycle progression in a synergistic and Rb-dependent
manner. Mol Cancer. 10(55)2011.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Shi Y, Liu C, Liu X, Tang DG and Wang J:
The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC)
growth and the CD44hi stem-like NSCLC cells. PLoS One.
9(e90022)2014.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Wahlquist C, Jeong D, Rojas-Muñoz A, Kho
C, Lee A, Mitsuyama S, van Mil A, Park WJ, Sluijter JP, Doevendans
PA, et al: Inhibition of miR-25 improves cardiac contractility in
the failing heart. Nature. 508:531–535. 2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Harrington EA, Bebbington D, Moore J,
Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C,
Hercend T, Diu-Hercend A, et al: VX-680, a potent and selective
small-molecule inhibitor of the Aurora kinases, suppresses tumor
growth in vivo. Nat Med. 10:262–267. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
76
|
Dar AA, Goff LW, Majid S, Berlin J and
El-Rifai W: Aurora kinase inhibitors-rising stars in cancer
therapeutics? Mol Cancer Ther. 9:268–278. 2010.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Görgün G, Calabrese E, Hideshima T, Ecsedy
J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, et al: A
novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and
cell-cycle arrest in multiple myeloma. Blood. 115:5202–5213.
2010.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Hannak E, Kirkham M, Hyman AA and Oegema
K: Aurora-A kinase is required for centrosome maturation in
Caenorhabditis elegans. J Cell Biol. 155:1109–1116. 2001.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Marumoto T, Zhang D and Saya H: Aurora-A-a
guardian of poles. Nat Rev Cancer. 5:42–50. 2005.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Hirota T, Kunitoku N, Sasayama T, Marumoto
T, Zhang D, Nitta M, Hatakeyama K and Saya H: Aurora-A and an
interacting activator, the LIM protein Ajuba, are required for
mitotic commitment in human cells. Cell. 114:585–598.
2003.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Lentini L, Amato A, Schillaci T, Insalaco
L and Di Leonardo A: Aurora-A transcriptional silencing and
vincristine treatment show a synergistic effect in human tumor
cells. Oncol Res. 17:115–125. 2008.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Kaestner P, Stolz A and Bastians H:
Determinants for the efficiency of anticancer drugs targeting
either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
Mol Cancer Ther. 8:2046–2056. 2009.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Compérat E, Bièche I, Dargère D,
Laurendeau I, Vieillefond A, Benoit G, Vidaud M, Camparo P, Capron
F, Verret C, et al: Gene expression study of Aurora-A reveals
implication during bladder carcinogenesis and increasing values in
invasive urothelial cancer. Urology. 72:873–877. 2008.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Lee ECY, Frolov A, Li R, Ayala G and
Greenberg NM: Targeting Aurora kinases for the treatment of
prostate cancer. Cancer Res. 66:4996–5002. 2006.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Matarasso N, Bar-Shira A, Rozovski U,
Rosner S and Orr-Urtreger A: Functional analysis of the Aurora
kinase A Ile31 allelic variant in human prostate. Neoplasia.
9:707–715. 2007.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Kumano M, Miyake H, Terakawa T, Furukawa J
and Fujisawa M: Suppressed tumour growth and enhanced
chemosensitivity by RNA interference targeting Aurora-A in the PC3
human prostate cancer model. BJU Int. 106:121–127. 2010.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Addepalli MK, Ray KB, Kumar B, Ramnath RL,
Chile S and Rao H: RNAi-mediated knockdown of AURKB and EGFR shows
enhanced therapeutic efficacy in prostate tumor regression. Gene
Ther. 17:352–359. 2010.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Li Y, Zhang ZF, Chen J, Huang D, Ding Y,
Tan MH, Qian CN, Resau JH, Kim H and The BT: VX680/MK-0457, a
potent and selective Aurora kinase inhibitor, targets both tumor
and endothelial cells in clear cell renal cell carcinoma. Am J
Transl Res. 2:296–308. 2010.PubMed/NCBI
|
|
89
|
Wang X, Dong L, Xie J, Tong T and Zhan Q:
Stable knockdown of Aurora-A by vector-based RNA interference in
human esophageal squamous cell carcinoma cell line inhibits tumor
cell proliferation, invasion and enhances apoptosis. Cancer Biol
Ther. 8:1852–1859. 2009.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Pérez de Castro I, de Cárcer G, Montoya G
and Malumbres M: Emerging cancer therapeutic opportunities by
inhibiting mitotic kinases. Curr Opin Pharmacol. 8:375–383.
2008.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Tung YT, Chen HL, Lee CY, Chou YC, Lee PY,
Tsai HC, Lin YL and Chen CM: Active component of Danshen (Salvia
miltiorrhiza Bunge), tanshinone I, attenuates lung
tumorigenesis via inhibitions of VEGF, cyclin A, and cyclin B
expressions. Evid Based Complement Alternat Med.
2013(319247)2013.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Tian H, Li Y, Mei J, Cao L, Yin J, Liu Z,
Chen J and Li X: Effects of Salvia miltiorrhiza extract on
lung adenocarcinoma. Exp Ther Med. 22(794)2021.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Gao F, Li M, Liu W and Li W: Inhibition of
EGFR signaling and activation of mitochondrial apoptosis contribute
to tanshinone IIA-mediated tumor suppression in non-small cell lung
cancer cells. OncoTargets Ther. 13:2757–2769. 2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Wang M, Tang W, Gong N and Liu P: Sodium
Danshensu inhibits the progression of lung cancer by regulating
PI3K/Akt signaling pathway. Drug Dev Res. 83:88–96. 2022.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Lu Z, Zhou R, Kong Y, Wang J, Xia W, Guo
J, Liu J, Sun H, Liu K, Yang J, et al: S-equol, a secondary
metabolite of natural anticancer isoflavone daidzein, inhibits
prostate cancer growth in vitro and in vivo, though activating the
Akt/FOXO3a pathway. Curr Cancer Drug Targets. 16:455–465.
2016.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Li Q, Hu K, Tang S, Xu LF and Luo YC:
Anti-tumor activity of tanshinone IIA in combined with
cyclophosphamide against Lewis mice with lung cancer. Asian Pac J
Trop Med. 9:1084–1088. 2016.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Bi L, Yan X, Yang Y, Qian L, Tian Y, Mao
JH and Chen W: The component formula of Salvia miltiorrhiza
and Panax ginseng induces apoptosis and inhibits cell
invasion and migration through targeting PTEN in lung cancer cells.
Oncotarget. 8:101599–101613. 2017.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Yan XJ, Yang Y, Bi L, Chen SS, Zhu JJ and
Chen WP: Effects of component formula of Salviae
miltiorrhizae Radix et Rhizoma and Ginseng Radix et Rhizoma on
cell proliferation, apoptosis and skeleton in lung cancer A549
cells. Zhongguo Zhong Yao Za Zhi. 39:4436–4441. 2014.PubMed/NCBI(In Chinese).
|
|
99
|
Zinnah KMA and Park SY: Sensitizing
TRAIL-resistant A549 lung cancer cells and enhancing TRAIL-induced
apoptosis with the antidepressant amitriptyline. Oncol Rep.
46(144)2021.PubMed/NCBI View Article : Google Scholar
|
|
100
|
He J, Zhou Q, Yuan S, Wang Y, Chen X and
Qin J: The growth-inhibiting effect and its molecular mechanism of
Tanshinone on human lung cancer cell line in vitro. Zhongguo Fei Ai
Za Zhi. 5:123–125. 2002.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
101
|
Hu H, Zhang Y, Huang F and Deng H:
Inhibition of proliferation and induction of apoptosis by
tanshinone II A in NCI-H460 cell. Zhong Yao Cai. 28:301–304.
2005.PubMed/NCBI(In Chinese).
|
|
102
|
Liu F, Yu G, Wang G, Liu H, Wu X, Wang Q,
Liu M, Liao K, Wu M, Cheng X and Hao H: An NQO1-initiated and
p53-independent apoptotic pathway determines the anti-tumor effect
of tanshinone IIA against non-small cell lung cancer. PLoS One.
7(e42138)2012.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Zhang J, Wang J, Jiang JY, Liu SD, Fu K
and Liu HY: Tanshinone IIA induces cytochrome c-mediated caspase
cascade apoptosis in A549 human lung cancer cells via the JNK
pathway. Int J Oncol. 45:683–690. 2014.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Kim EO, Kang SE, Im CR, Lee JH, Ahn KS,
Yang WM, Um JY, Lee SG and Yun M: Tanshinone IIA induces TRAIL
sensitization of human lung cancer cells through selective ER
stress induction. Int J Oncol. 48:2205–2212. 2016.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Liu HY, Li QR, Cheng XF, Wang GJ and Hao
HP: NAMPT inhibition synergizes with NQO1-targeting agents in
inducing apoptotic cell death in non-small cell lung cancer cells.
Chin J Nat Med. 14:582–589. 2016.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Israels LG and Israels ED: Apoptosis.
Oncologist. 4:332–339. 1999.PubMed/NCBI
|
|
107
|
Xu X, Lai Y and Hua ZC: Apoptosis and
apoptotic body: Disease message and therapeutic target potentials.
Biosci Rep. 39(BSR20180992)2019.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Pistritto G, Trisciuoglio D, Ceci C,
Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: Function
and dysfunction of its modulators and targeted therapeutic
strategies. Aging (Albany NY). 8:603–619. 2016.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Wu GS: TRAIL as a target in anti-cancer
therapy. Cancer Lett. 285:1–5. 2009.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Chang CC, Lai JS, Tsai CS, Ma SW, Lin JY,
Huang LR, Lu CH, Liao EC and Ho TF: Proapoptotic and
TRAIL-sensitizing constituents isolated from Salvia militiorrhiza
(Danshen). J Biosci Bioeng. 116:516–523. 2013.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Shen L, Lou Z and Zhang G, Xu G and Zhang
G: Diterpenoid tanshinones, the extract from Danshen (Radix
Salviae miltiorrhizae) induced apoptosis in nine human
cancer cell lines. J Tradit Chin Med. 36:514–521. 2016.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Lou ZH, Xia RM, Li XJ, Cheng RB, Shao KD
and Zhang GJ: Anti-lung cancer mechanisms of diterpenoid tanshinone
via endoplasmic reticulum stress-mediated apoptosis signal pathway.
Zhongguo Zhong Yao Za Zhi. 43:4900–4907. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
113
|
Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y,
Liu T, Wang D, Ge H and Mo SL: The antitumor effect of tanshinone
IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on
the human non-small cell lung cancer A549 cell line. Acta Pharm Sin
B. 5:554–563. 2015.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Chen D, Lin XX, Huang WH, Zhang W, Tan ZR,
Peng JB, Wang YC, Guo Y, Hu DL and Chen Y: Sodium tanshinone IIA
sulfonate and its interactions with human CYP450s. Xenobiotica.
46:1085–1092. 2016.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Zhou X, Pan Y, Wang Y, Wang B, Yan Y, Qu Y
and Ke X: Tanshinones induce tumor cell apoptosis via directly
targeting FHIT. Sci Rep. 11(12217)2021.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Wu CY, Yang YH, Lin YS, Chang GH, Tsai MS,
Hsu CM, Yeh RA, Shu LH, Cheng YC and Liu HT: Dihydroisotanshinone I
induced ferroptosis and apoptosis of lung cancer cells. Biomed
Pharmacother. 139(111585)2021.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Singh R and Cuervo AM: Autophagy in the
cellular energetic balance. Cell Metab. 13:495–504. 2011.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Sridhar S, Botbol Y, Macian F and Cuervo
AM: Autophagy and disease: Always two sides to a problem. J Pathol.
226:255–273. 2012.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Fukuda K, Kobayashi A and Watabe K: The
role of tumor-associated macrophage in tumor progression. Front
Biosci (Schol Ed). 4:787–798. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
120
|
Li GG, Guo ZZ, Ma XF, Cao N, Geng SN,
Zheng YQ, Meng MJ, Lin HH, Han G and Du GJ: The M2 macrophages
induce autophagic vascular disorder and promote mouse sensitivity
to urethane-related lung carcinogenesis. Dev Comp Immunol.
59:89–98. 2016.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Hao W, Zhang X, Zhao W, Zhu H, Liu ZY, Lu
J and Chen X: Cryptotanshinone induces pro-death autophagy through
JNK signaling mediated by reactive oxygen species generation in
lung cancer cells. Anticancer Agents Med Chem. 16:593–600.
2016.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Guo S, Luo W, Liu L, Pang X, Zhu H, Liu A,
Lu J, Ma DL, Leung CH, Wang Y and Chen X: Isocryptotanshinone, a
STAT3 inhibitor, induces apoptosis and pro-death autophagy in A549
lung cancer cells. J Drug Target. 24:934–942. 2016.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Zhang B, Ma Z, Li X, Zhang C, Shao Y, Liu
Z, Li Y and Jin Y: Tanshinones suppress non-small cell lung cancer
through up-regulating miR-137. Acta Biochim Biophys Sin (Shanghai).
48:768–770. 2016.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Gao H, Sun W, Zhao W, Hao W, Leung CH, Lu
J and Chen X: Total tanshinones-induced apoptosis and autophagy via
reactive oxygen species in lung cancer 95D cells. Am J Chin Med.
43:1265–1279. 2015.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Yuan A, Hsiao YJ, Chen HY, Chen HW, Ho CC,
Chen YY, Liu YC, Hong TH, Yu SL, Chen JJ and Yang PC: Opposite
effects of M1 and M2 macrophage subtypes on lung cancer
progression. Sci Rep. 5(14273)2015.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Valente AJ, Graves DT, Vialle-Valentin CE,
Delgado R and Schwartz CJ: Purification of a monocyte chemotactic
factor secreted by nonhuman primate vascular cells in culture.
Biochemistry. 27:4162–4168. 1988.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Yoshimura T, Robinson EA, Tanaka S,
Appella E, Kuratsu J and Leonard EJ: Purification and amino acid
analysis of two human glioma-derived monocyte chemoattractants. J
Exp Med. 169:1449–1459. 1989.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Schmall A, Al-Tamari HM, Herold S,
Kampschulte M, Weigert A, Wietelmann A, Vipotnik N, Grimminger F,
Seeger W, Pullamsetti SS and Savai R: Macrophage and cancer cell
cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving
lung cancer. Am J Respir Crit Care Med. 191:437–447.
2015.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Man Y, Yang L, Zhang D and Bi Y:
Cryptotanshinone inhibits lung tumor growth by increasing
CD4+ T cell cytotoxicity through activation of the
JAK2/STAT4 pathway. Oncol Lett. 12:4094–4098. 2016.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Liu S, Han Z, Trivett AL, Lin H, Hannifin
S, Yang D and Oppenheim JJ: Cryptotanshinone has curative dual
anti-proliferative and immunotherapeutic effects on mouse Lewis
lung carcinoma. Cancer Immunol Immunother. 68:1059–1071.
2019.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Wu CY, Cherng JY, Yang YH, Lin CL, Kuan
FC, Lin YY, Lin YS, Shu LH, Cheng YC, Liu HT, et al: Danshen
improves survival of patients with advanced lung cancer and
targeting the relationship between macrophages and lung cancer
cells. Oncotarget. 8:90925–90947. 2017.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Lee CY, Sher HF, Chen HW, Liu CC, Chen CH,
Lin CS, Yang PC, Tsay HS and Chen JJ: Anticancer effects of
tanshinone I in human non-small cell lung cancer. Mol Cancer Ther.
7:3527–3538. 2008.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix
MJ, Wu R and Wu CW: Selection of invasive and metastatic
subpopulations from a human lung adenocarcinoma cell line. Am J
Respir Cell Mol Biol. 17:353–360. 1997.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Chen JJ, Peck K, Hong TM, Yang SC, Sher
YP, Shih JY, Wu R, Cheng JL, Roffler SR, Wu CW and Yang PC: Global
analysis of gene expression in invasion by a lung cancer model.
Cancer Res. 61:5223–5230. 2001.PubMed/NCBI
|
|
136
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Tammela T, Enholm B, Alitalo K and
Paavonen K: The biology of vascular endothelial growth factors.
Cardiovasc Res. 65:550–563. 2005.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676.
2003.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Jin L, Chen C, Huang L, Bu L, Zhang L and
Yang Q: Salvianolic acid A blocks vasculogenic mimicry formation in
human non-small cell lung cancer via PI3K/Akt/mTOR signalling. Clin
Exp Pharmacol Physiol. 48:508–514. 2021.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Zhang Y, Wang L, Chen Y and Qing C:
Anti-angiogenic activity of salvicine. Pharm Biol. 51:1061–1065.
2013.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Zhang P, Pei Y and Qi Y: Influence of
blood-activating drugs on adhesion and invasion of cells in lung
cancer patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 19:103–105.
1999.PubMed/NCBI(In Chinese).
|
|
142
|
Wang H, Zhang Y, Zhang Y, Liu W and Wang
J: Cryptotanshinone inhibits lung cancer invasion via
microRNA-133a/matrix metalloproteinase 14 regulation. Oncol Lett.
18:2554–2559. 2019.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Xie J, Liu JH, Liu H, Liao XZ, Chen Y, Lin
MG, Gu YY, Liu TL, Wang DM, Ge H and Mo SL: Tanshinone IIA combined
with adriamycin inhibited malignant biological behaviors of NSCLC
A549 cell line in a synergistic way. BMC Cancer.
16(899)2016.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Zhang XZ, Qian SS, Zhang YJ and Wang RQ:
Salvia miltiorrhiza: A source for anti-Alzheimer's disease
drugs. Pharm Biol. 54:18–24. 2016.PubMed/NCBI View Article : Google Scholar
|
|
145
|
He SB, Zhang BX, Wang HH, Wang Y and Qiao
YJ: Study on mechanism of Salvia miltiorrhiza treating
cardiovascular disease through auxiliary mechanism elucidation
system for Chinese medicine. Zhongguo Zhong Yao Za Zhi.
40:3713–3717. 2015.PubMed/NCBI(In Chinese).
|
|
146
|
Chuang MT, Ho FM, Wu CC, Zhuang SY, Lin
SY, Suk FM and Liang YC: 15,16-Dihydrotanshinone I, a compound of
Salvia miltiorrhiza bunge, induces apoptosis through
inducing endoplasmic reticular stress in human prostate carcinoma
cells. Evid Based Complement Alternat Med.
2011(865435)2011.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Chen FY, Bi L, Qian L, Gao J, Jiang YC and
Chen WP: Identification of multidrug resistance gene MDR1
associated microRNA of salvianolic acid A reversal in lung cancer.
Zhongguo Zhong Yao Za Zhi. 41:3279–3284. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
148
|
Tang XL, Yan L, Zhu L, Jiao DM, Chen J and
Chen QY: Salvianolic acid A reverses cisplatin resistance in lung
cancer A549 cells by targeting c-met and attenuating Akt/mTOR
pathway. J Pharmacol Sci. 135:1–7. 2017.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Xia C, Bai X, Hou X, Gou X, Wang Y, Zeng
H, Huang M and Jin J: Cryptotanshinone reverses cisplatin
resistance of human lung carcinoma A549 cells through
down-regulating Nrf2 pathway. Cell Physiol Biochem. 37:816–824.
2015.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Jiang Y, You F, Zhu J, Zheng C, Yan R and
Zeng J: Cryptotanshinone ameliorates radiation-induced lung injury
in rats. Evid Based Complement Alternat Med.
2019(1908416)2019.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Liao XZ, Gao Y, Huang S, Chen ZZ, Sun LL,
Liu JH, Chen HR, Yu L, Zhang JX and Lin LZ: Tanshinone IIA combined
with cisplatin synergistically inhibits non-small-cell lung cancer
in vitro and in vivo via down-regulating the phosphatidylinositol
3-kinase/Akt signalling pathway. Phytother Res. 33:2298–2309.
2019.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Wang R, Luo Z, Zhang H and Wang T:
Tanshinone IIA reverses gefitinib-resistance in human
non-small-cell lung cancer via regulation of VEGFR/Akt pathway.
Onco Targets Ther. 12:9355–9365. 2019.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Cao HY, Ding RL, Li M, Yang MN, Yang LL,
Wu JB, Yang B, Wang J, Luo CL and Wen QL: Danshensu, a major
water-soluble component of Salvia miltiorrhiza, enhances the
radioresponse for Lewis lung carcinoma xenografts in mice. Oncol
Lett. 13:605–612. 2017.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Kim JH, Jeong SJ, Kwon TR, Yun SM, Jung
JH, Kim M, Lee HJ, Lee MH, Ko SG, Chen CY and Kim SH:
Cryptotanshinone enhances TNF-α-induced apoptosis in chronic
myeloid leukemia KBM-5 cells. Apoptosis. 16:696–707.
2011.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Su CC: Tanshinone IIA potentiates the
efficacy of 5-FU in Colo205 colon cancer cells in vivo
through downregulation of P-gp and LC3-II. Exp Ther Med. 3:555–559.
2012.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Ye Y, Xu W, Zhong W, Li Y and Wang C:
Combination treatment with dihydrotanshinone I and irradiation
enhances apoptotic effects in human cervical cancer by HPV E6
down-regulation and caspases activation. Mol Cell Biochem.
363:191–202. 2012.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Xia R and Chen X: Effects of Danshen
injection on the malignant obstructive jaundice in the SD rat
model. J Huazhong Univ Sci Technolog Med Sci. 26:686–689.
2006.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Wang T, Fu X and Wang Z: Danshen Formulae
for Cancer: A Systematic Review and Meta-Analysis of High-Quality
Randomized Controlled Trials. Evid Based Complement Altern Med.
2019(2310639)2019.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Yang Y, Qiu S, Qian L, Tian Y, Chen Y, Bi
L and Chen W: OCF can repress tumor metastasis by inhibiting
epithelial-mesenchymal transition involved in PTEN/PI3K/AKT pathway
in lung cancer cells. PLoS One. 12(e0174021)2017.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Geng QX, Zhu XL and Zhang XH: Effect of
combined therapy of shenmai and compound danshen injection on
myocardial reperfusion injury after percutaneous coronary
intervention in patients with acute myocardial infarction. Zhongguo
Zhong Xi Yi Jie He Za Zhi. 24:496–499. 2004.PubMed/NCBI(In Chinese).
|
|
161
|
Zhang X, Luo W, Zhao W, Lu J and Chen X:
Isocryptotanshinone induced apoptosis and activated MAPK signaling
in human breast cancer MCF-7 cells. J Breast Cancer. 18:112–118.
2015.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Di Cesare Mannelli L, Piccolo M, Maione F,
Ferraro MG, Irace C, De Feo V, Ghelardini C and Mascolo N:
Tanshinones from Salvia miltiorrhiza Bunge revert
chemotherapy-induced neuropathic pain and reduce glioblastoma cells
malignancy. Biomed Pharmacother. 105:1042–1049. 2018.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Shen YD, Tian YX, Bu XZ and Gu LQ: Natural
tanshinone-like heterocyclic-fused ortho-quinones from
regioselective Diels-Alder reaction: Synthesis and cytotoxicity
evaluation. Eur J Med Chem. 44:3915–3921. 2009.PubMed/NCBI View Article : Google Scholar
|
